FOLH1 and prostate cancer: The implementation of theranostics in oncologic nuclear medicine has exhibited immense potential in improving patient outcomes in prostate cancer with the implementation of [68Ga]Ga-PSMA-11 PET and [177Lu]Lu-PSMA-617 into clinical practice.